Meeder Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.85K | Buy |
+106
| New | +$3.85K | ﹤0.01% | 747 |
|
|
2024
Q3 | – | Sell |
-90
| Closed | -$3.7K | – | 933 |
|
|
2024
Q2 | $3.7K | Buy |
90
+3
| +3% | +$123 | ﹤0.01% | 808 |
|
|
2024
Q1 | $4.06K | Buy |
+87
| New | +$4.06K | ﹤0.01% | 654 |
|
|
2022
Q2 | – | Sell |
-149
| Closed | -$11K | – | 2374 |
|
|
2022
Q1 | $11K | Sell |
149
-1,158
| -89% | -$85.5K | ﹤0.01% | 1519 |
|
|
2021
Q4 | $110K | Sell |
1,307
-1,316
| -50% | -$111K | 0.01% | 390 |
|
|
2021
Q3 | $236K | Buy |
2,623
+943
| +56% | +$84.8K | 0.01% | 673 |
|
|
2021
Q2 | $160K | Sell |
1,680
-299
| -15% | -$28.5K | 0.01% | 786 |
|
|
2021
Q1 | $225K | Buy |
+1,979
| New | +$225K | 0.01% | 695 |
|
|
2020
Q4 | – | Sell |
-3,098
| Closed | -$254K | – | 2151 |
|
|
2020
Q3 | $254K | Buy |
3,098
+2,125
| +218% | +$174K | 0.02% | 548 |
|
|
2020
Q2 | $77K | Buy |
973
+868
| +827% | +$68.7K | 0.01% | 821 |
|
|
2020
Q1 | $5K | Buy |
+105
| New | +$5K | ﹤0.01% | 1799 |
|
|
2019
Q4 | – | Sell |
-124
| Closed | -$5K | – | 2382 |
|
|
2019
Q3 | $5K | Buy |
+124
| New | +$5K | ﹤0.01% | 1770 |
|
|
2019
Q2 | – | Sell |
-598
| Closed | -$41K | – | 2123 |
|
|
2019
Q1 | $41K | Buy |
598
+456
| +321% | +$31.3K | ﹤0.01% | 919 |
|
|
2018
Q4 | $6K | Buy |
+142
| New | +$6K | ﹤0.01% | 1378 |
|
|
2018
Q1 | – | Sell |
-74
| Closed | -$3K | – | 1713 |
|
|
2017
Q4 | $3K | Buy |
+74
| New | +$3K | ﹤0.01% | 1437 |
|
|
2017
Q3 | – | Sell |
-99
| Closed | -$6K | – | 1735 |
|
|
2017
Q2 | $6K | Buy |
+99
| New | +$6K | ﹤0.01% | 1151 |
|